DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,539,995 | +3.7% | 102,942 | +0.3% | 2.44% | +7.8% |
| Q2 2023 | $24,632,722 | -5.4% | 102,636 | -0.6% | 2.26% | -12.8% |
| Q1 2023 | $26,029,004 | -3.9% | 103,273 | +1.2% | 2.60% | -16.1% |
| Q4 2022 | $27,074,241 | +6.3% | 102,005 | +3.4% | 3.10% | -4.8% |
| Q3 2022 | $25,468,000 | +4.2% | 98,604 | +2.3% | 3.25% | +14.5% |
| Q2 2022 | $24,437,000 | -13.9% | 96,390 | -0.3% | 2.84% | +11.8% |
| Q1 2022 | $28,369,000 | -11.7% | 96,712 | -0.9% | 2.54% | -6.4% |
| Q4 2021 | $32,110,000 | +10.6% | 97,597 | +2.4% | 2.71% | +0.6% |
| Q3 2021 | $29,030,000 | +12.7% | 95,355 | -0.7% | 2.70% | +13.2% |
| Q2 2021 | $25,764,000 | +19.2% | 96,004 | -0.0% | 2.38% | +4.1% |
| Q1 2021 | $21,612,000 | -2.0% | 96,017 | -3.3% | 2.29% | -4.4% |
| Q4 2020 | $22,061,000 | +3.6% | 99,310 | +0.4% | 2.39% | -3.9% |
| Q3 2020 | $21,299,000 | +23.0% | 98,912 | +1.0% | 2.49% | +5.0% |
| Q2 2020 | $17,322,000 | +28.1% | 97,956 | -1.7% | 2.37% | +4.1% |
| Q1 2020 | $13,523,000 | -12.8% | 99,691 | -1.3% | 2.28% | +7.9% |
| Q4 2019 | $15,503,000 | +6.0% | 101,009 | -0.3% | 2.11% | -7.2% |
| Q3 2019 | $14,626,000 | +1.5% | 101,266 | +0.4% | 2.28% | +2.6% |
| Q2 2019 | $14,411,000 | +8.3% | 100,834 | +0.1% | 2.22% | +1.4% |
| Q1 2019 | $13,302,000 | +22.6% | 100,760 | -4.2% | 2.19% | +4.2% |
| Q4 2018 | $10,846,000 | +3.7% | 105,182 | +9.3% | 2.10% | +31.6% |
| Q3 2018 | $10,458,000 | +10.6% | 96,245 | +0.5% | 1.60% | +0.3% |
| Q2 2018 | $9,454,000 | +15.2% | 95,800 | +14.3% | 1.59% | +11.2% |
| Q1 2018 | $8,209,000 | +3.4% | 83,839 | -2.0% | 1.43% | -2.7% |
| Q4 2017 | $7,940,000 | -16.9% | 85,537 | -23.3% | 1.47% | -23.6% |
| Q3 2017 | $9,560,000 | -23.2% | 111,449 | -24.5% | 1.92% | -28.9% |
| Q2 2017 | $12,451,000 | -1.1% | 147,537 | +0.3% | 2.70% | -3.0% |
| Q1 2017 | $12,586,000 | +7.5% | 147,152 | -2.1% | 2.79% | +0.3% |
| Q4 2016 | $11,705,000 | +28.9% | 150,378 | +29.8% | 2.78% | +27.5% |
| Q3 2016 | $9,083,000 | +17.6% | 115,863 | +51.5% | 2.18% | +17.5% |
| Q2 2016 | $7,722,000 | -3.2% | 76,456 | -9.1% | 1.86% | -3.2% |
| Q1 2016 | $7,980,000 | +18.6% | 84,121 | +16.1% | 1.92% | +21.9% |
| Q4 2015 | $6,730,000 | +117.1% | 72,456 | +99.1% | 1.57% | +101.7% |
| Q3 2015 | $3,100,000 | – | 36,386 | – | 0.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |